Boston, MA, March 06, 2017 --(PR.com
)-- Interventional cardiology deals with the catheter based techniques for the treatment of cardiovascular diseases such as coronary and peripheral artery diseases, valvular and congenital heart diseases and structural heart diseases. As estimated by IQ4I Research the interventional cardiology global is expected to grow at high single digit CAGR to reach $46,124.1 million by 2023. The Interventional cardiology global market by products is segmented into catheters, stents, valves, interventional diagnostic devices, transcatheter heart pump and others. Interventional cardiology market by applications includes diagnostic catheterization, coronary interventions, peripheral interventions and structural heart.
Among the products stents held the highest share due to wide acceptance of stent procedures, a minimal invasive surgery with less risk of complications than open surgery. Transcatheter heart pump segment is project to grow at a very high double digit CAGR. Abiomed, U.S. based medical device company has developed world’s smallest catheter based heart pump that provides hemodynamic support to the heart. The Impella heart pump (Impella series - Impella 2.5, Impella 5.0, Impella CP, and Impella RP) is FDA approved and presently is one of the factors for driving Interventional cardiology market.
Among various Interventional cardiology applications, coronary interventions held the highest share and is expected to grow at a high single digit CAGR. Structural heart segment is the fastest growing market with a double digit CAGR. Major companies are adopting acquisition strategy in the expansion of cardiovascular and structural heart devices product portfolio, for instance, in January 2017, Abbott Laboratories acquired St. Jude medical. Transcatheter Mitral Valve Replacement (TMVR), cardiac remodelling, catheter based heart pump are some of the technological advancements that are going to drive the interventional cardiology market in coming years.
The Interventional cardiology global market based on geography is divided into North America, Europe, Asia-Pacific and Rest of the world. North American region commanded the largest revenue and to grow at high single digit CAGR.
Major players in the interventional cardiology global market are Abiomed (U.S.), Abbott Laboratories (U.S.), Boston Scientific (U.S.), B. Braun (Germany), C.R. Bard (U.S.), Cook Medical (U.S), Edwards Lifesciences (U.S.), Johnson &Johnson (U.S.), Medtronic PLC. (Ireland), Terumo Corporation (Japan) and W.L.Gore & Associates, Inc. (U.S.).
BioVentrix, (U.S.), Biotronik GMBH & Co. (Germany), Cardiovascular Systems, Inc. (U.S.), Cardiva Medical, Inc.(U.S.), Cardiokinetix (U.S.), Procyrion (U.S.), Cardinal Health (U.S.), Getinge Group (Sweden), Goodman Co., Ltd. (Japan), InspireMed Ltd.(Israel), Lepu Medical (China), Lombard Medical Technologies (U.K.), Meril Life Sciences Pvt. Ltd.(India) and MicroPort Scientific Corporation (China) are some of the emerging players in the interventional cardiology market.